A detailed history of Jacobs Levy Equity Management, Inc transactions in Regenxbio Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 89,218 shares of RGNX stock, worth $993,888. This represents 0.0% of its overall portfolio holdings.

Number of Shares
89,218
Previous 152,437 41.47%
Holding current value
$993,888
Previous $1.78 Million 47.56%
% of portfolio
0.0%
Previous 0.01%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.49 - $14.39 $663,167 - $909,721
-63,219 Reduced 41.47%
89,218 $935,000
Q2 2024

Aug 14, 2024

SELL
$11.51 - $21.53 $1.61 Million - $3.01 Million
-139,904 Reduced 47.86%
152,437 $1.78 Million
Q1 2024

May 15, 2024

SELL
$12.17 - $24.61 $4.9 Million - $9.91 Million
-402,843 Reduced 57.95%
292,341 $6.16 Million
Q4 2023

Feb 14, 2024

BUY
$12.89 - $20.82 $1.71 Million - $2.76 Million
132,793 Added 23.61%
695,184 $12.5 Million
Q3 2023

Nov 16, 2023

BUY
$16.46 - $19.99 $24,574 - $29,845
1,493 Added 0.27%
562,391 $9.26 Million
Q2 2023

Aug 14, 2023

SELL
$17.23 - $21.71 $1.23 Million - $1.55 Million
-71,480 Reduced 11.3%
560,898 $11.2 Million
Q1 2023

May 15, 2023

BUY
$18.08 - $24.55 $10.9 Million - $14.9 Million
605,255 Added 2231.52%
632,378 $12 Million
Q4 2022

Feb 14, 2023

BUY
$20.4 - $24.73 $337,232 - $408,811
16,531 Added 156.07%
27,123 $615,000
Q3 2022

Nov 15, 2022

SELL
$22.29 - $35.04 $3.29 Million - $5.17 Million
-147,660 Reduced 93.31%
10,592 $280,000
Q2 2022

Aug 15, 2022

SELL
$19.35 - $35.04 $322,371 - $583,766
-16,660 Reduced 9.52%
158,252 $3.91 Million
Q1 2022

May 16, 2022

BUY
$24.62 - $34.31 $4.31 Million - $6 Million
174,912 New
174,912 $5.81 Million
Q3 2021

Nov 15, 2021

SELL
$29.09 - $45.68 $5.22 Million - $8.2 Million
-179,521 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$32.46 - $40.48 $387,669 - $483,452
-11,943 Reduced 6.24%
179,521 $6.97 Million
Q1 2021

May 17, 2021

BUY
$33.61 - $49.95 $5.53 Million - $8.21 Million
164,416 Added 607.87%
191,464 $6.53 Million
Q4 2020

Feb 16, 2021

SELL
$26.52 - $49.35 $40,257 - $74,913
-1,518 Reduced 5.31%
27,048 $1.23 Million
Q3 2020

Nov 16, 2020

SELL
$27.01 - $40.26 $142,099 - $211,807
-5,261 Reduced 15.55%
28,566 $786,000
Q2 2020

Aug 17, 2020

BUY
$27.75 - $43.44 $938,699 - $1.47 Million
33,827 New
33,827 $1.25 Million

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $482M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.